Valuation: Celestra Inc.

Market Cap 13.41B 9.33M 8.07M 7.52M 6.9M 13.03M 890M 13.23M 88.57M 34.72M 443M 35.04M 34.28M 1.47B P/E 2024
-0.4x
P/E 2025 -1.14x
Enterprise Value 17.19B 11.97M 10.35M 9.64M 8.85M 16.71M 1.14B 16.97M 114M 44.53M 568M 44.94M 43.96M 1.88B EV / Sales 2024
5.8x
EV / Sales 2025 8.56x
Free-Float
78.31%
Yield 2024 *
-
Yield 2025 -
1 day-20.63%
1 week-0.00%
Current month-0.00%
1 month-0.00%
3 months-0.00%
6 months-0.00%
Current year-0.00%
3 years 4,245
Extreme 4245
63,000
5 years 4,245
Extreme 4245
145,500
10 years 4,245
Extreme 4245
261,500
Manager TitleAgeSince
Chief Executive Officer 30 2024-03-28
Comptroller/Controller/Auditor 47 2025-03-30
Director TitleAgeSince
Director/Board Member 30 2024-03-28
Director/Board Member 42 2025-09-24
Director/Board Member 41 2024-06-13
Date Insider Type Main position Quantity % Market Cap.
6/17/24 Sell

Chief Executive Officer

100,000 -
Change 5-day change 1-year change 3-year change Capi.($)
-20.63%-0.00%-0.00%-88.78% 9.33M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -3.41%-2.44%+55.25%+69.37% 25.04B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2024 2025
Net sales 8.5B 5.92M 5.12M 4.77M 4.38M 8.26M 565M 8.39M 56.17M 22.02M 281M 22.22M 21.74M 930M 2.01B 1.4M 1.21M 1.13M 1.03M 1.95M 133M 1.98M 13.27M 5.2M 66.38M 5.25M 5.13M 220M
Net income -46.92B -32.66M -28.25M -26.32M -24.17M -45.61M -3.12B -46.31M -310M -122M -1.55B -123M -120M -5.14B -11.77B -8.19M -7.09M -6.6M -6.06M -11.44M -782M -11.62M -77.77M -30.49M -389M -30.77M -30.1M -1.29B
Net Debt 29.34B 20.42M 17.66M 16.46M 15.11M 28.52M 1.95B 28.96M 194M 75.99M 970M 76.69M 75.02M 3.21B 3.79B 2.63M 2.28M 2.12M 1.95M 3.68M 251M 3.74M 25.01M 9.8M 125M 9.89M 9.68M 414M
Logo Celestra Inc.
Celestra Inc, formerly Clinomics Inc, is a Korea-based company principally operates precision medical business based on genome-based healthcare and liquid biopsy platforms. The Company provides genome-based healthcare products and services that predict physical characteristics and diseases based on genome diagnosis and examination. The Company is engaged in the sale of medical devices and cancer diagnosis and monitoring that extract blood cells and deoxyribo nucleic acid (DNA) to diagnose patients. The Company is developing multi-omics-based early diagnosis service technology for diseases such as cancer.
Employees
48
  1. Stock Market
  2. Stocks
  3. A352770 Stock